Anti-TNF-α Antibodies Suppress the Development of Experimental Autoimmune Myasthenia Gravis

This publication has 27 references indexed in Scilit:

• Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment
  Annals of the Rheumatic Diseases, 1999
• The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards?
  Annals of the Rheumatic Diseases, 1999
• Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis
  Gene Therapy, 1999
• Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
  European Journal of Immunology, 1997
• Altered Immune Responses in Interleukin 10 Transgenic Mice
  The Journal of Experimental Medicine, 1997
• Myasthenia Gravis
  New England Journal of Medicine, 1994
• Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG)
  Clinical and Experimental Immunology, 1993
• Towards a comprehensive view of immunoglobulin class switching
  Immunology Today, 1993
• Biological properties of interleukin 10
  Immunology Today, 1992
• γ-Interferon is one of several direct B cell-maturing lymphokines
  Nature, 1984